Search

Your search keyword '"Mariano Valdes Chavarri"' showing total 3 results
Start Over Author "Mariano Valdes Chavarri"
3 results on '"Mariano Valdes Chavarri"'

1. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement

Author

Alberto Ortiz Saez, Andrés Íñiguez Romo, Jose Antonio Baz Alonso, Saleta Fernández Barbeira, Emilio Galán, Sergio Raposeiras Roubin, Raúl Moreno, Eduardo Molina Navarro, Guillermo Bastos Fernández, Rafael Romaguera, Francisco Calvo Iglesias, Pablo Juan Salvadores, Ángel Cequier Fillat, Juan Ocampo Miguez, Mariano Valdes Chavarri, Antonio De Miguel Castro, Antonio Serra Peñaranda, Ignacio Cruz Gonzalez, Victor Alfonso Jimenez Diaz, and Antonio Tello-Montoliu

Subjects
constricción patológica, Aortic valve, medicine.medical_specialty, trombosis, Terapia antitrombótica, medicine.medical_treatment, Estenosis aórtica, enfermedades cardiovasculares, Constriction, Pathologic, macromolecular substances, 030204 cardiovascular system & hematology, Ensaio REAC-TAVI, 03 medical and health sciences, 0302 clinical medicine, P2Y12, Valve replacement, aortic s, Internal medicine, medicine, Clinical endpoint, cardiovascular diseases, 030212 general & internal medicine, Heart Valve Prosthesis Implantation, implantación de prótesis valvulares cardíacas, business.industry, Thrombosis, medicine.disease, Clopidogrel, Stenosis, medicine.anatomical_structure, Cardiovascular Diseases, Aortic Valve, Cardiology, Cardiology and Cardiovascular Medicine, business, válvula aórtica, Ticagrelor, medicine.drug
Abstract

OBJECTIVES: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI. BACKGROUND: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence. METHODS: This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU

Published
2019

2. TCT CONNECT-390 Safety and Efficacy of Sirolimus-Eluting Stent System in All-Comers Real-World Population With Coronary Artery Stenosis: The MILES-Global Study

Author

Martin Hudec, A.J.J. IJsselmuiden, Ramiro Trillo, Hyeon-Cheol Gwon, Myung Ho Jeong, Yi-chih Wang, José Marques da Costa, In-Ho Chae, Min-Ji Charng, Oteh Maskon, Jose Moreu Burgos, G. Mayurathan, Hristo Mateev, Antonio Serra, Bela Merkely, Rita Theotonio, Chun Yao Huang, Samih Lawand, Philip Mar, Andriy Khokhlov, Beatriz Montilla, Mariano Valdes Chavarri, and null Mohammad Sadeghian

Subjects
Cardiology and Cardiovascular Medicine
Published
2020

3. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Author

Nick E.J. West, Neil J. Weissman, Ian T Meredith, Leif Thuesen, Paul Barragan, Henning Kelbæk, Robert Whitbourn, Jacek Kubica, Iwar Sjögren, Dominic J. Allocco, Adrian P. Banning, Stefan Verheye, Darren L. Walters, Mónica Masotti, Mariano Valdes Chavarri, Rod Stables, D. Scott, and Keith D. Dawkins

Subjects
Target lesion, medicine.medical_specialty, Time Factors, Polymers, Everolimus eluting stent, medicine.medical_treatment, Myocardial Infarction, Coronary Artery Disease, Kaplan-Meier Estimate, Bioabsorbable polymer, Coronary Angiography, Prosthesis Design, Coronary Restenosis, Percutaneous Coronary Intervention, Coated Materials, Biocompatible, Predictive Value of Tests, Risk Factors, medicine, Humans, Stent thrombosis, Everolimus, Ultrasonography, Interventional, Sirolimus, Chi-Square Distribution, business.industry, Coronary Thrombosis, Australia, Stent, Cardiovascular Agents, Drug-Eluting Stents, Coronary Vessels, Current analysis, Surgery, Clinical trial, Europe, Treatment Outcome, Cardiology and Cardiovascular Medicine, business, medicine.drug, New Zealand
Abstract

AIMS: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial. METHODS AND RESULTS: EVOLVE recruited 291 patients from 29 centres. At six months, IVUS-assessed in-stent net volume obstruction was 3.40 ± 5.06% for PROMUS Element (PE) vs. 2.68 ± 4.60% for SYNERGY (p=0.34) and 3.09 ± 4.29% for SYNERGY ½ dose (p=0.68 vs. PE). There were no significant differences between groups for any other measured IVUS parameter including resolved, persistent, and late-acquired incomplete stent apposition (ISA). At two years, target lesion failure (TLF) was 6.1% for PE vs. 5.5% for SYNERGY (p=0.87) and 5.2% for SYNERGY ½ dose (p=0.81). There were no significant differences between groups for cardiac death, repeat revascularisation, MI or stent thrombosis through two years. CONCLUSIONS: At six months, everolimus delivered from an ultrathin bioabsorbable abluminal polymer resulted in equivalent net volume obstruction and ISA compared with a permanent polymer EES. There were no significant differences between PE and either SYNERGY stent for any major cardiac endpoint through two years. Clinical trials number: NCT01135225.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results